AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Chemotherapy-Induced Hair and Nail Changes: Pathogenesis, Prevention, and Treatment

Description

The talk reviews chemotherapy-induced hair and nail changes, emphasizing that alopecia is common, distressing, and often under-discussed, with many patients feeling unprepared for hair loss, texture changes, and loss of eyebrows, eyelashes, and body hair. It explains the pathogenesis as damage to rapidly dividing hair matrix cells causing anagen effluvium, sometimes followed by telogen effluvium, and notes that more intensive regimens lead to faster and more severe loss, with some patients developing persistent or permanent alopecia. Clinical patterns can resemble androgenetic, traction, or frictional alopecia, and hair may regrow with altered color or texture. The strongest preventive evidence is for scalp cooling, which works by reducing scalp blood flow and chemo exposure; it is most useful for short infusion regimens but limited by cost, discomfort, and contraindications such as cold-related disorders, skull radiation, active scalp malignancy, or very prolonged chemotherapy. Other therapies have weaker evidence, though topical minoxidil is commonly used, especially for persistent chemotherapy-induced alopecia, where some patients can still regrow hair even after months or years. Additional options discussed include eyelash treatment with bimatoprost, possible adjunctive spironolactone or finasteride in selected patients, topical calcitriol, and photobiomodulation/red light therapy. For nail toxicity, the lecture highlights common findings such as melanonychia, Beau’s lines, ridging, paronychia, and photo-onycholysis, caused by matrix toxicity, inflammation, vascular injury, and photosensitivity. Preventive and treatment measures include nail lacquer, cooling gloves and socks, topical steroids, doxycycline for paronychia, silver nitrate for pyogenic granulomas, and red light therapy, with cooling also potentially reducing neuropathy.

View more

Conclusions

  • Chemotherapy commonly causes visible hair loss and nail toxicity, and these changes can substantially worsen quality of life and treatment satisfaction.
  • Patients are often not adequately counseled about alopecia, so proactive counseling and oncodermatology support are important parts of care.
  • Chemotherapy-induced alopecia usually results from damage to rapidly dividing hair matrix cells, with additional contributions from telogen effluvium, stress, and nutritional deficiency.
  • Hair loss timing and severity depend on the regimen, with more toxic schedules causing earlier, more complete loss and some agents such as taxanes causing persistent alopecia.
  • Scalp cooling is the best-supported preventive strategy for chemotherapy-induced alopecia, working for a majority of patients but limited by cost, logistics, and tolerability.
  • When scalp cooling is not feasible, topical minoxidil and possibly oral minoxidil for persistent chemotherapy-induced alopecia appear to offer the most practical benefit, although evidence remains limited.
  • Even long-standing persistent chemotherapy-induced alopecia may improve with low-dose oral minoxidil, and quality of life can improve alongside hair regrowth.
  • Other proposed hair-loss treatments such as bimatoprost, spironolactone, calcitriol, and photobiomodulation may help in selected cases, but the evidence is much thinner than for minoxidil and scalp cooling.
  • Chemotherapy-related nail changes are common and diverse, with melanonychia being especially frequent, but more severe inflammatory or traumatic nail complications also occur.
  • Nail changes arise through multiple mechanisms including matrix toxicity, vascular injury, inflammation, and photosensitivity.
  • Supportive measures such as nail lacquer, cooling gloves and socks, and targeted treatment of paronychia or pyogenic granulomas can reduce morbidity from nail toxicity.
  • Photobiomodulation and extremity cooling show promise for reducing nail toxicity and neuropathy, but broader validation is still needed.
  • Overall, the presentation argues for early dermatologic involvement to prevent, mitigate, and treat hair and nail toxicities so cancer therapy is easier for patients to tolerate.
  • Carelle N, et al. Cancer 2002;95(1):155-63.
  • Özusağlam E. Florence Nightingale J Nurs. 2021;29(3):361-370.
  • Paus R, et al. Lancet Oncol 2013;14:e50–59.
  • Freites-Martinez A, et al. JAAD 2019;80(50):1179-1196.
  • Wang S, et al. Supportive Care Cancer. 2021;29:6943-6956.
  • A randomized trial of minoxidil in chemotherapy-induced alopecia. 1996.#10.1016/s0190-9622(96)90500-9
  • Bhoyrul B, et al. JAMA Dermatol. 2021;157(11):1135-1342.
  • Freites-Martinez A, JAAD, 2019.
  • Bhoyrul B, et al. JAMA Dermatol. 2021;157(11):1135-1342.
  • Bommareddy K, et al. JAMA Dermatol. 2022;158(3):275-282.
  • Lacouture M, et al. Breast Cancer Res Treat. 2021 February;186(1):107–114.
  • Lodewijckx J, et al. Supportive Care Cancer 2023;31:269.
  • Trivedi M, et al. Indian J Dermatol. 202;69(3):205-211.
  • Alshari O, et al. Breast Cancer. 2020;14:1-4.